Fundraisings and IPOs

1 2 3 69
Number of results: 1365
Date Company Amount Funding type Investors Therapeutic area Type of Information
2018-08-13 Orchard Therapeutics (UK) $150 Million series C financing round ArrowMark Partners (USA - CO) Cormorant Asset Management (USA - MA) Foresite Capital (USA - NY) RA Capital Management (USA - MA) Perceptive Advisors (USA - NY) RTW Investments (USA - NY) Venrock (USA - CA) Foresite Capital (USA - NY) Sphera Global Healthcare (Spain) Medison Ventures Driehaus Capital Management (USA - IL) Ghost Tree Capital Group (USA - NY) Temasek (Singpore) Baillie Gifford (UK) Cowen Healthcare (USA - NY) Agent Capital (USA - MA) Rare diseases - Genetic diseases Series C financing round
2018-08-06 Pharmaxis (Australia) A$24 million (£13.4 million - €15.35 million) financing round Arix Bioscience (UK) BVF Partners (USA - CA) other existing shareholders Fibrotic diseases - Inflammatory diseases Financing round
2018-07-31 AC Immune (Switzerland) $117.5 million private placement Neurological diseases - CNS diseases Private placement
2018-07-23 Azafaros (The Netherlands) seed financing round BioGeneration Ventures (The Netherlands) Rare diseases - Genetic diseases - Metabolic diseases Financing round
2018-07-06 Oncologie (USA - MA - China) $16.5 million seed financing round Nan Fung Life Sciences (China) Pivotal bioVenture Partners China Fund (China) China Merchant Bank Investments (China) Volcanics Ventures (China) Cancer - Oncology Financing round
2018-06-25 Avrobio (USA - MA) $114.7 million IPO Cancer - Oncology - Rare diseases - Genetic diseases - Lysosomal diseases IPO
2018-02-05 Metrion Biosciences (UK) £200 000 grant Innovate UK Biomedical Catalyst Feasibility Award scheme (UK) Autoimmune diseases - Neurodegenerative diseases Grant
2018-02-02 Viking Therapeutics (USA - PA) $55 million private placement Endocrinological diseases - Metabolic diseases Private placement
2018-02-02 Medivir (Sweden) 155 million SEK (€ 15.75 million) Infectious diseases Private placement
2018-02-01 Avrobio (USA - MA) $60 million series B financing round Cormorant Asset Management and Surveyor Capital (a Citadel company), and included participation by Aisling, Brace Pharma Capital, Eventide Asset Management and Morningside, along with existing investors Atlas Venture, SV Health Investors and Clarus Ventures. Cancer - Oncology - Rare diseases - Genetic diseases Series B financing round
2018-01-29 Audentes Therapeutics (USA - CA) $231.4 million private placement Rare diseases - Genetic diseases Private placement
2018-01-23 Tmunity Therapeutics (USA - PA) $ 100 million series A financing round Ping An Ventures (China) Parker Institute for Cancer Immunotherapy (USA - CA) Gilead Sciences (USA - CA) Be The Match BioTherapies University of Pennsylvania (USA - PA) Lilly Asia Ventures (China) Cancer - Oncology - Autoimmune diseases - Infectious diseases Series A financing round
2018-01-23 Skyhawk Therapeutics (USA - MA) $ 8 million financing round Tim Disney, the Duke of Bedford, Alexandria Venture Investments (USA - MA) and other undisclosed private investors Cancer - Oncology - Neurological diseases Financing round
2018-01-22 Avexis (USA - IL) $431.9 million private placement Rare diseases - Genetic diseases - Neuromuscular diseases Private placement
2018-01-16 Arbutus Biopharma (Canada) US$116.4 million private placement Roivant Sciences (CH - USA) Infectious diseases Private placement
2018-01-05 Advicenne (France) €27.8 million IPO Rare diseases - Genetic diseases - Pediatric diseases IPO
2018-01-04 Enterome Bioscience (France) €40 million loan European Investment Bank (EIB) Liver diseases - Hepatic diseases - Inflammatory diseases - Digestive diseases - Cancer - Oncology Loan
2018-01-04 Enterome Bioscience (France) €32 million ($38.5 million) series D financing round BMS (USA - NY) Principia SGR (Italy) Health For Life Capital (Seventure) (France) Lundbeckfond Venture (Denmark) Nestlé Health Science (Switzerland) Omnes Capital (France) Liver diseases - Hepatic diseases - Inflammatory diseases - Digestive diseases - Cancer - Oncology Series D financing round
2018-01-04 Acticor Biotech (France) €3.9 million financing round Primer Capital (Russia) Anaxago (France) CapDecisif Management (France) private investors Cerebrovascular diseases Financing round
2017-12-29 Armo BioScience IPO Cancer - Oncology IPO